Erasca Reports First Quarter 2026 Business Updates and Financial Results

▤ Summary

Erasca shared first-quarter 2026 business updates and financial results for its RAS/MAPK-targeted oncology pipeline. The company reported encouraging early data for ERAS-0015 and continued progress on ERAS-4001, along with new collaboration agreements with Merck and Tango Therapeutics. It also expanded the territory in its ERAS-0015 license agreement and completed an upsized public offering earlier in the year. Erasca ended the quarter with about $409 million in cash and marketable securities and expects that capital to fund operations into the second half of 2028.

▦ Linked Companies